

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Ischemia; reperfusion injury	Hypoxia-inducible factor 1 α (HIF1A; HIF1 α)	Studies in mice suggest that adenoviral delivery of HIF1A could help treat critical limb ischemia in diabetics. In diabetic mice with ligated lateral femoral arteries, intramuscular injection of an adenoviral vector expressing constitutively activated HIF1A increased recovery compared with injection of adenoviral vector expressing a control protein. Next steps include testing the gene therapy in clinical trials.	Findings patented; available for licensing	Sarkar, K. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Oct. 19, 2009; doi:10.1073/pnas.0910561106 Contact: Gregg L. Semenza, The Johns Hopkins University School of Medicine, Baltimore, Md. e-mail: gsemenza@jhmi.edu
		SciBX 2(42); doi:10.1038/scibx.2009.1568 Published online Oct. 29, 2009		